Novartis
JP Morgan Healthcare Conference Day 1: Novartis, Gilead, Johnson & Johnson, EQRx, Mirati, and More
Companies provided updates on precision oncology programs for CAR T-cell and biomarker-targeted therapies and announced plans for diagnostic and predictive tests.
Ahead of an expected radiopharmaceutical approval in the New Year, oncologists and drugmakers are taking stock of imaging eligibility requirements and access disparities.
Novartis, BeiGene Ink Licensing Deal for TIGIT Inhibitor Ociperlimab
Novartis will pay BeiGene $300 million upfront for rights to develop and commercialize the agent, which BeiGene is studying with a checkpoint inhibitor in NSCLC and solid tumors.Â
Kura Oncology Begins Trial of Tipifarnib, Novartis' Piqray in Head and Neck Cancer
The Phase I/II trial will enroll patients with recurrent or metastatic HRAS- or PIK3CA-dependent head and neck cancer.
Novartis' Kymriah Flops in Second-Line LBCL, Puzzling Oncologists After Yescarta, Breyanzi Successes
At ASH, researchers tried to explain why Novartis' CAR T-cell therapy failed to improve event-free survival for second-line LBCL patients whereas similar therapies succeeded.